Blood Biological Products Market Size, Share, Growth, and Industry Analysis, By Type (Coagulation Factor, Immune Globulin, Albumin and Other), By Application (Immunology, Hematology and Other), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

BLOOD BIOLOGICAL PRODUCTS MARKET OVERVIEW

The global blood biological products market stood at USD 40.66 Billion in 2026 and maintaining a strong growth trajectory to reach USD 78.76 Billion by 2035 with a CAGR of 7.6% from 2026 to 2035.

Blood biologicals describe a group of healing agents made from one or more human blood or plasma fractions. These products are highly essential in the current day medicines as they are use in managing different illnesses, specifically ones that are related to blood disorders, immunologic deficiencies, and some infections. Blood biological products are usually made by a selective process that involved collection, separation, processing and purification of blood or the plasma from the healthy donor.

KEY FINDINGS

COVID-19 IMPACT

Market Growth restrained by the Pandemic due to Disruptions in Blood Donations

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

Like with many aspects of daily life, the pandemic had an effect on blood donations that manifested soon after its onset. People were afraid of going out due to risks of infection, social distancing measures and lockdowns also affected many potential blood donors – common blood donation events were limited or canceled. This led to crises in the always scarce blood sort required for production of many biological goods including red blood cells, platelets and plasma-based products.

LATEST TRENDS

Rise in Demand for Plasma-Derived Therapies to Propel Market Growth

The new market trend observed in blood biological products is a continuous increase in the demand for plasma-derived therapies due to a large number of indicated applications. Plasma derived products are obtained from human plasma which is the liquid constituting portion of the vein blood which contains proteins, antibodies al other vein biomolecules. Such therapies are now popular due to the testifying results of improved various disease and health conditions such as immune deficiencies, bleeding disorders and neurological disorders. The growth in demand for plasma derived products is one such driver that can help in the explanatory frame of this escalating trend.

• According to the World Health Organization (WHO), approximately 118.54 million blood donations are collected globally every year, with around 40% of these donations coming from high-income countries that represent only 16% of the global population. This imbalance has encouraged governments to strengthen national blood donation campaigns and build modern plasma collection infrastructure. As a result, several countries have expanded digital donor registries and introduced national awareness programs to maintain stable supplies of blood-derived biological products.
• According to the U.S. Food and Drug Administration (FDA) and industry associations, around 85% of plasma processing facilities globally utilize pathogen-reduction technologies (PRT) to enhance the safety of blood-derived biological products. Additionally, automated plasma fractionation systems have demonstrated up to 18% higher plasma yield compared with traditional manual processing, improving efficiency in the production of immunoglobulins, albumin, and coagulation factors used in critical therapies.

Download Free Sample to learn more about this report

BLOOD BIOLOGICAL PRODUCTS MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Coagulation Factor, Immune Globulin, Albumin and Other.

• Coagulation Factor- Coagulation factors are paramount proteins that are involved in clot formation among patients with prolonged bleeding rates and excessive clot formation. These are essential in various diseases such as; hemorrhagic states; bleeding diathesis; hemophilia and such other related complications.

• Immune Globulin- Antibodies are proteins which are a part of the immune system and which are used to solve and determine the distinction between foreign materials and pathogens in the body. Human-derived immunoglobulins exist in many preparations that are applied in immunological deficiencies, autoimmune diseases and certain infections.

• Albumin- Albumin is one of the major proteins with a capacity to combine with plasma, it is thus responsible for controlling the blood volume and pressure in the circulatory system. Albumin-based therapeutic human plasma products are called for situations when the patient has hypovolemia, or when the concentration of albumin in the body is low.

By Application

Based on application the market can be categorized into Immunology, Hematology, and Others.

• Immunology- In immunology, the blood BPPs have many important roles to play as in the treatment of immune deficient diseases and autoimmune diseases. Immunoglobulins derived from plasma concentrates assist in raising the immunological status of individuals suffering from some varieties of PIDs like SCID, CVID, or specific antibody deficiency.

• Hematology- Blood biological products play crucial roles in handling hematology and management of patient who suffers from bleeding disorder and or blood clotting deficiencies. Antithromrombic derived from plasma to correct the disease that is required for clotting are Factor VIII for hemophilia A and Factor IX for hemophilia B. They are used as prescription drugs to serve as replacement therapies to the missing clotting factors, with the aim of preventing and treating hemorrhagic complications of inherited coagulation disorders.

DRIVING FACTORS

Increasing Incidence of Chronic Diseases to Drive Market Advancement

One of the key driving factors in the Blood Biological Products market growth is the Increasing Incidence of Chronic Diseases. In this case, the role of blood bioproducts is pivotal in the advancement of systematic demands area, especially when it comes to chronic diseases where their rate is constantly increasing. Perennial diseases like hemophilia, immune deficiencies, autoimmune diseases, and some hereditary diseases need continuous medications and treatments that relieve the symptoms, mitigate the risk of the development of other symptoms, and increase the patient’s quality of life. For example, hemophilia is a hereditary disease that affects the coagulation process of the blood and requires frequent administration of clotting factors based on plasma for Both prophylactic and interventional purposes. Like those with primary immune deficiencies, they do not possess the basic antibodies necessary to combat diseases and depend on immunoglobulin therapies, which are taken from plasma to boost their immune system and minimize their vulnerability to diseases.

• According to the World Health Organization (WHO), more than 118 million blood donations are collected annually worldwide, supporting millions of transfusion procedures in hospitals. Furthermore, clinical data indicates that emergency departments alone used over 5 million plasma units for trauma treatment in a single year, highlighting the growing dependence of healthcare systems on blood biological products for critical care, surgery, and immune-related disorders.
• According to the Plasma Protein Therapeutics Association (PPTA), plasma-derived therapies are used in the treatment of more than 10,000 rare and chronic diseases, including hemophilia, immune deficiencies, and neurological disorders. Additionally, patients with chronic immune deficiency may require 10–15 plasma donations annually to sustain long-term treatment, which significantly drives the demand for plasma-based biological products across global healthcare systems.

Advancements in Biotechnology and Manufacturing to Expand the Market

The importance of biotechnology and production processes has been considered as the key growth and development forces of the blood biological products market. These technological developments have greatly boosted the process in creating, manufacturing, and making accessible essential treatments that are acquired from the constituents of blood, typically plasma and clotting factors. Contributions of biotechnology make the process of extracting, purifying, and modifying the blood bio-products to be more efficient. Advancements in plasma fractionation processes consequently mean that this separation and isolation is even more distinct and that the yields of the proteins and factors that are involved possess greater therapeutic value.

RESTRAINING FACTOR

High Manufacturing Costs Poses Potential Impediments to Market Growth

Manufacturing as a cost element remains a limitation within the blood biological products market given it has direct influence on possibility of manufacturing the products sustainably and meet the needs of the systems and patients. The specific operations associated with creating blood biological products, especially those that originate from plasma, are highly intricate, costly, and technical in nature. Firstly, plasma-derived therapies are more likely to feel the squeeze due to the need for specialized facilities enhanced with plasma fractionation technologies as well as the need for quality controls over such. Plasma fractionation is the process of refining plasma, also called the liquid part of the blood, into its pure elements like immunoglobulins, clotting factors that include Factor VIII and Factor IX, and albumin. These processes are highly technical and complex and need the services of well-trained and qualified human resource in the company as well as compliance with regulatory measures that govern production of these products as a way of ensuring that companies produce safe and effective products.

• According to the World Health Organization (WHO), global demand for plasma donors exceeds supply by approximately 20%, with the most critical shortages reported in several Asian and developing economies. Limited donor participation and demographic challenges create supply constraints for plasma fractionation facilities and biopharmaceutical manufacturers producing blood biological products.
• According to WHO blood safety data, high-income countries collect a median of 31.5 blood donations per 1,000 people, whereas lower-middle-income countries collect only 6.6 donations per 1,000 people and low-income countries just 5 donations per 1,000 people. This disparity restricts access to plasma-derived medicines in developing regions and limits consistent supply for the blood biological products market.
• Download Free Sample to learn more about this report

•  

BLOOD BIOLOGICAL PRODUCTS MARKET REGIONAL INSIGHTS

North America to Dominate the Market due to Advanced Healthcare Infrastructure

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

North America has emerged as the most dominant region in the Blood Biological Products market share due to a convergence of factors that propel its leadership in this dynamic industry. North America also has fully developed healthcare systems and comprehensive and clear regulatory frameworks that regulate the production, development, and delivery of blood biological products. Proximity of key strategic stakeholders including the most dominant pharmaceutical firms, biotechnology companies, and research organizations lends itself to both innovation and market dominance.

KEY INDUSTRY PLAYERS

Key Players Transforming the Commercial Bar Cabinet Landscape through Innovation and Global Strategy

Major industry players are pivotal in shaping the Blood Biological Products market, driving change through a dual strategy of continuous innovation and a well-thought-out global presence. By consistently introducing inventive solutions and staying at the forefront of technological progress, these key players redefine the industry's standards. Simultaneously, their expansive global reach enables effective market penetration, addressing diverse needs across borders. The seamless blend of groundbreaking innovation and a strategic international footprint positions these players as not only market leaders but also as architects of transformative shifts within the dynamic domain of Blood Biological Products.

• Takeda (Japan): According to company and regulatory disclosures, Takeda Pharmaceutical Company develops plasma-derived therapies used in the treatment of rare and chronic diseases such as hemophilia and immunodeficiency disorders. The company operates a large plasma collection network and supports the production of therapies used to treat thousands of patients globally suffering from more than 10,000 rare medical conditions addressed by plasma-derived treatments.
• Grifols (Spain): According to industry and regulatory data, Grifols operates a global plasma collection network with hundreds of centers supporting the processing of millions of plasma donations annually. The company is among the leading manufacturers supplying plasma-derived medicines to healthcare systems in over 100 countries, contributing to the production of essential therapies such as immunoglobulins, albumin, and clotting factors used in critical medical treatments.

List Of Top Blood Biological Products Companies

• Takeda (Japan)
• Grifols (Spain)
• Octapharma (Switzerland)
• LFB Group (France)
• Biotest (Germany)

INDUSTRIAL DEVELOPMENT

Jan 2024: Chales River Laboratories launched Endosafe Trillium Cartridge, a new animal-free testing solution for robust bacterial endotoxin texting. 

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.